Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
暂无分享,去创建一个
S. Goodman | J. Ioannidis | D. Moher | L. Hemkens | Fahim Ebrahimi | V. Gloy | N. Khanna | P. Janiaud | N. Haber | Emily R. Smith | A. Schmitt | M. Hepprich | C. Axfors
[1] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[2] F. Polack,et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.
[3] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.
[4] D. Zarin,et al. Lack of harmonization of coronavirus disease ordinal scales , 2020, Clinical trials.
[5] M. Landray,et al. Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2020, medRxiv.
[6] A. Tewari,et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial , 2020, medRxiv.
[7] D. Follmann,et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia , 2020, The New England journal of medicine.
[8] S. Atkin,et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease , 2020, Scientific Reports.
[9] R. Maiwall,et al. Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial , 2020, medRxiv.
[10] T. Bhatnagar,et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) , 2020, BMJ.
[11] Jennifer L. Bell,et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2020, The Lancet.
[12] J. Alcamí,et al. Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial , 2020, medRxiv.
[13] Eva Petkova,et al. Pooling Data From Individual Clinical Trials in the COVID-19 Era. , 2020, JAMA.
[14] Patrick W. Johnson,et al. Safety Update , 2020, Mayo Clinic Proceedings.
[15] Jennifer L. Bell,et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. , 2020, medRxiv.
[16] M. M. van der Eerden,et al. Convalescent Plasma for COVID-19. A randomized clinical trial , 2020, medRxiv.
[17] G. Koh. Faculty Opinions recommendation of Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[18] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[19] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.
[20] L. Ren,et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[21] L. Hemkens,et al. COVID-evidence: a living database of trials on interventions for COVID-19 , 2020 .
[22] Natalie S Blencowe,et al. RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.
[23] Dean Langan,et al. Comparative performance of heterogeneity variance estimators in meta‐analysis: a review of simulation studies , 2016, Research synthesis methods.
[24] J. McGowan,et al. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. , 2016, Journal of clinical epidemiology.
[25] W. Lim,et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.
[26] George F Borm,et al. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.
[27] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[28] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.